Geoffrey R. Oxnard, MD
Early-stage lung cancers are detectable in cell-free DNA (cfDNA) using a genome-wide sequencing approach, according to findings of The Circulating Cancer Genome Atlas (CCGA) study.
The study enrolled 12,292 patients, of which 70% with cancer and 30% without. Two initial cohorts were created with a training set (1733 clinically evaluable samples, 127 positive for lung cancer) and a test set (n = 980 clinically evaluable samples, 47 positive for lung cancer).
... to read the full story